Expert international faculty present weekly, concise MedicalMinute updates, host biweekly Question and Answer Webinars, and author a continually updated downloadable slideset including the latest data on COVID-19 epidemiology and clinical management; specific topics include best practices and ongoing research in screening, prevention, diagnosis, disease management, and treatment for diverse patient populations.
Get free and unlimited CME/CE access. Create your account now.
In this presentation, Dr. Sharon Lewin reviews recent data on investigational therapies for COVID-19, including TMPRSS2 inhibitors, CRISPR-Cas13, and interferon lambda.
In this presentation, Vikram Mukherjee, MD, reviews recent studies on thromboprophylaxis and anticoagulation in persons with COVID-19.
In this presentation, Dr. Jens Lundgren reviews tests for SARS-CoV-2 infection, with emphasis on assays that detect viral antigens.
In this presentation, Arthur Kim, MD, reviews recent EUAs for baricitinib, bamlanivimab, and casirivimab/imdevimab, as well as NIH guideline recommendations for ivermectin.
In this presentation, Dr. Roger Paredes reviews safety and efficacy data on COVID-19 vaccines, as well as considerations for vaccine rollout.
In this concise presentation, Professor Yee-Sin Leo reviews vaccine hesitancy data, and the factors that impact vaccine hesitancy.
In this presentation, Dr. Paul Sax reviews data on the relationship between HIV infection and COVID-19 outcomes.
In this presentation, Dr. Roger Paredes reviews the implications and prevalence of mutations in SARS-CoV-2.
In this presentation, Dr. Vikram Mukherjee reviews recent studies on the epidemiology of COVID-19 in healthcare workers.
In this presentation, Professor Jens D. Lundgren reviews the currently available case report literature on reinfection with SARS-CoV-2.
In this presentation, Professor Sharon Lewin discusses the FDA approval of remdesivir and the data from the ACTT-1 and WHO SOLIDARITY trials.
In this presentation, Professor Leo Yee-Sin discusses the incidence of coinfections and superinfections in patients with COVID-19.
In this presentation, Jens D. Lundgren, MD, DMSc, discusses recently published and unpublished data on the use of immunomodulatory agents to treat COVID-19.
In this presentation, Dr. Vikram Mukherjee discusses key recommendations for the management of common comorbidities in the context of COVID-19.
In this presentation, Dr. Adaora Adimora discusses recently published clinical trial and meta-analysis data on the use of corticosteroids to treat COVID-19.
In this presentation, Dr. Wong Chen Seong discusses what is known about COVID-19 symptom persistence and the long-term pulmonary, cardiovascular, and neurologic sequelae in recovered patients
In this presentation, Professor David Heymann provides an overview of the concept of herd immunity and considerations for estimating the herd immunity threshold for SARS-CoV-2.
In this presentation, Professor Jens D. Lundgren discusses the theory behind using convalescent plasma to treat infectious disease and the current evidence and recommendations regarding its use to treat patients with COVID-19.
In this presentation, Professor Sharon Lewin discusses the recent data on the durability of antibody and T cell responses to SARS-CoV-2 and the implications for reinfection.
In this concise presentation, Dr. Vikramjit Mukherjee discusses the presentation and burden of coagulopathy in COVID-19 and the data and recommendations on preventative therapy.
In this presentation, Professor David Heymann provides an update on the development and utility of current diagnostic tests for SARS-CoV-2, with special consideration to how various methods can be used in an epidemiological approach to limit community transmission.
In this presentation, Dr. Sigal Yawetz discusses the current data on COVID-19 risk and disease severity in pregnant women and newborns, treatment options during pregnancy, and best practices for postpartum management of mothers infected with COVID-19.
In this presentation, Professor David Heymann discusses the current data on SARS-CoV-2 transmission, including mechanisms, timing, and protective strategies.
In this presentation, Professor Sharon Lewin discusses the rapid development of SARS-CoV-2 vaccines and the emerging safety and immunogenicity data from clinical trials investigating several vaccine candidates.
In this concise presentation, Dr. Vikramjit Mukherjee discusses presentation and disease severity of COVID-19 in children and the diagnosis, incidence, and management of multisystem inflammatory syndrome in children.
In this presentation, Professor Jens D. Lundgren discusses the immune response to SARS-CoV-2 in relation to disease presentation and severity in immunocompromised patients, including solid organ transplant patients, patients on immunomodulatory therapies, and patients with HIV.
In this concise presentation, Professor Jens D. Lundgren discusses the RECOVERY trial data and the updated guidance on administering dexamethasone to treat COVID-19.
In this presentation, Dr. Vikramjit Mukherjee discusses medical management for severe to critical COVID-19, including the latest guidance and information on evolving treatment options.
In this presentation, Dr. Adaora Adimora discusses the disproportionate number of COVID-19 cases and deaths among Black and Latinx populations and factors that influence these disparities.
In this presentation, Dr. Adaora Adimora discusses medical management for mild to moderate COVID-19, including current treatment recommendations and data on investigational therapies.
In this presentation, Professor Leo Yee-Sin discusses COVID-19 clinical manifestation, including the current data on common symptoms, risk factors for severe disease, and disease course.
In this presentation, Professor Jens D. Lundgren discusses COVID-19 diagnosis, including clinical suspicion of infection and temporal considerations for detecting SARS-CoV-2 using current methods.
In this presentation, Professor Sharon Lewin discusses the kinetics of the antibody response following SARS-CoV-2 infection, current tests for antibody detection, and the use of serology assays in COVID-19 diagnosis and epidemiological studies
In this concise presentation, Dr. Vikramjit Mukherjee discusses the indications, dosing guidelines, and special considerations outlined in the FDA emergency use authorization of remdesivir for treatment of COVID-19.
In Part 1 of this ongoing 12-part COVID-19 series, listen to a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data on evidence-based antiviral therapy for severe disease followed by answers to critical clinician questions on COVID-19 transmission, diagnosis, and management from frontline provider Vikramjit Mukherjee, MD.
In Part 2 of this ongoing 12-part COVID-19 series, listen to a brief update on the latest incidence trends, a concise guide to viral diagnostic testing, and new data on investigational treatment options followed by answers to critical clinician questions on COVID-19 transmission, diagnosis, and management from frontline provider Jens D. Lundgren, MD, DMSc.
In Part 3 of this ongoing 12-part COVID-19 series, listen to a brief update on the latest incidence trends and a concise guide to the management of mild and moderate disease, followed by answers to critical clinician questions on COVID-19 transmission, diagnosis, and management from frontline provider Sharon Lewin, AO, FRACP, PhD, FAAHMS.
In Part 4 of this ongoing 12-part COVID-19 series, listen to a brief update on the latest incidence trends and a concise summary of updates to the US National Institutes of Health and the Infectious Diseases Society of America recommendations for managing COVID-19, followed by answers to critical clinician questions on COVID-19 transmission, diagnosis, and management from frontline provider Vikramjit Mukherjee, MD.
In Part 5 of this ongoing 12-part COVID-19 series, listen to a brief update on the epidemiology of SARS-CoV-2 and evidence-based interventions for reducing transmission, followed by answers to critical clinician questions on COVID-19 transmission and mitigation by David Heymann, BA, MD, DTM&H.
In Part 6 of this ongoing 12-part COVID-19 series, listen to a brief update on vaccine development and treatment strategies, followed by answers to clinician questions on COVID-19 by Jens D. Lundgren, MD, DMSc.
In Part 7 of this ongoing 12-part COVID-19 series, listen to a brief update on COVID-19 risk and prevention strategies among healthcare workers by Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS.
In Part 8 of this ongoing COVID-19 series, listen to a brief update on current treatment options for COVID-19 by Paul E. Sax, MD.
In Part 9 of this ongoing COVID-19 series, listen to a brief update on key concepts in COVID-19 immunity and the latest information on treatment strategies by Lynora Saxinger, MD, FRCPC, CTropMed.
In Part 10 of this ongoing COVID-19 series, listen to a brief update on COVID-19 and HIV by Wong Chen Seong, MBBS, MRCP(UK), FAMS.
In Part 11 of this ongoing COVID-19 series, listen to a brief update on the role of interferons in COVID-19 by Sharon R. Lewin AO, FRACP, PhD, FAHMS.
In Part 12 of this ongoing COVID-19 series, listen to a brief update on strategies for moving forward and living safely within the continued COVID-19 pandemic by David Heymann, BA, MD, DTM&H.
In Part 13 of this ongoing COVID-19 series, listen to a brief update on monoclonal antibody treatments for COVID-19 and the recently released COVID-19 vaccine efficacy information from Jens D. Lundgren, MD, DMSc.
In Part 14 of this ongoing series, listen to a brief update on COVID-19 mortality trends from Vikramjit Mukherjee, MD, followed by his answers to clinicians' COVID-19 questions.
In Part 15 of this ongoing series, listen to a brief update on emerging COVID-19 variants from Roger Parades, MD, PhD, followed by his answers to clinicians’ COVID-19 questions.
In Part 16 of this ongoing series, listen to an update on immunity to emerging COVID-19 variants from Sharon R. Lewin, AO, FRACP, PhD, FAHMS, followed by her answers to COVID-19 questions.
In Part 17 of this ongoing series, listen to an update on the latest COVID-19 treatment data and guidelines from Arthur Kim, MD, followed by his answers to COVID-19 questions.
Slideset updated regularly to reflect the state of the COVID-19 pandemic and to include the latest data and guidance on best practices for diagnosis and prevention of transmission.
Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.
Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.
Slideset updated regularly to include the latest data and guidance on non-therapeutic and therapeutic treatments for COVID-19, including authorized and investigational agents.
Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants.
In this module, expert faculty answer clinician questions about risk factors for COVID-19 infection and severe disease, with an emphasis on special populations and patients with comorbidities. New questions will be added and responses will be further developed or adjusted often as more data emerge.
In this module, expert faculty answer clinician questions about COVID-19 diagnosis, transmission, and epidemiology. New questions will be added and responses will be further developed often as more data emerge.
In this module, expert faculty answer clinician questions about COVID-19 symptoms and disease course, including managing medical complications. New questions will be added and responses will be further developed often as more data emerge.
In this module, expert faculty answer clinician questions about COVID-19 treatment options. New questions will be added and responses will be further developed often as more data emerge.
In this module, expert faculty answer clinicians’ questions about COVID-19 vaccines and immunity. New questions will be added and responses will be further developed often as more data emerge.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.